Amachiza okucima i-COX akunokuba yinto entle
Ubuhlungu kunye nokuvuvukala, isikhalazo esona sikhulu sabantu ngexesha elithile ebomini babo kunye nesimo esiqhelekileyo sosuku lwabantu abaninzi abane-arthritis, kubangelwa yi-cyclooxygenase, okanye i-COX, emfutshane.
I-COX yi-enzyme eyenza i-prostanoids- prostaglandins , i-prostacyclins, kunye ne-thromboxanes-ezo zonke zijongene nokuphendula okuvuthayo.
Kuvela ukuba i-COX akuyona yonke into embi, kubalulekile nakwiinkqubo eziqhelekileyo zeselula.
Izidakamizwa ezijoliswe ekunqandeni i-COX ekukhuliseni ukuvuvukala, kubonakala ngathi yingcamango enhle, kodwa ngokukhusela i-COX, kukho ukuphazamiseka.
I-COX-1 ne-COX-2
Ngama-1990, kwafunyaniswa ukuba kukho iifom ezimbini ze-COX-1 ne-COX-2. Le ndlela yokugqibela yinto enqwenelekayo kubini. I-COX-1 iyaziwa ukuba ikhona kwiintlobo ezininzi. Kwiphepha lesisu, i-COX-1 igcina isilumko esisisigxina sesisu kwaye ikhusela isisu ukusuka kwimizi yokugaya. I-enzyme ikwabandakanyeka kwiintso kunye nomsebenzi weplatelet. I-COX-2 ifunyanwe ikakhulu kwiindawo zokuvuvukala.
Bobabini i-COX-1 kunye ne-COX-2 ingabangela intlungu kunye nokuvuvukala, kodwa ekubeni i-COX-1 injalo inzyme enenzuzo, ukusebenzisa iziyobisi ukuvimbela ingabi yinto efanelekileyo.
IiNSAID zivimbela i-COX
Izidakamizwa ezichasene nezidakamizwa (NonSA) ezithintekayo izidakamizwa (i-NSAID), eziqhelekileyo ukuba zonyango i-arthritis, zisebenza ngokuvimbela i-prostaglandin. I-NSAID zendabuko, njenge-ibuprofen kunye ne-naproxen, ingabangela iingxaki zesisu ngokuquka izilonda .
Ezi zi-NSAID ziyi-nonselective, oku kuthetha ukuba zivimbela zombini i-COX-1 kunye ne-COX-2. I-inhibition ye-COX-2 nge-NSAID yendabuko inceda iziphumo zayo ezichasayo, kodwa ukuphazamiseka kwe-COX-1 kungakhokelela kwimiphumo emibi njengezilonda, ixesha eliphumayo kunye neengxaki zezintso.
Ii-NSAID ze-COX-2 ezikhethiweyo
Ekupheleni kweminyaka yama-1990, iinkampani zamachiza zavelisa amayeza amaninzi ajoliswe kwi-COX-2 kuphela, ezi NSAID zaziyiCelebrex, iVioxx kunye ne-Bextra.
Kule ndawo, iCelebrex yiyo kuphela isicatshulwa esihlala kwimarike e-United States kwaye inobhokisi ebomnyama isilumkiso sokuba inomngcipheko wokuhlaselwa yintliziyo kunye nesifo.
Ekubeni ukuxothwa kweVixx ngo-2004, i-US Food and Drug Administration ihlolisise lonke iklasi leziyobisi, kuquka zonke ii-NSAID kunye ne-COX-2 inhibitors ezithengiswa ngaphaya kwe-counter okanye nge-prescription, kwaye zongezwa iibhokisi ezimnyama ezimiselweyo .
Ezinye ii-COX-2 inhibitors, i-Arcoxia ne-Prexige, ezisebenzisayo kwamanye amazwe, ziye zalahlwa yi-FDA. I-Prexige isuswe kwiimarike e-Australia kunye naseCanada ngenxa yokuxhatshazwa kwesibindi.
Abanye abaphandi bacinga ukuba, emva kokufumana amanqanaba aphantsi ka-COX-2 kwezinye izicubu ezingezangezikhuni, ukuba i-COX-2 inokudlala indima kwimisebenzi ethile eqhelekileyo yomzimba ngaphandle kokuvuvukala. Abaphandi e-UK baye bafumanisa ukuba i-COX-2 ingakhusela isifo se-atherosclerosis, igama lezonyango lokuqina kogqabi, ukuxinwa kunye nokuvala.
Ngelixa i-NSAID kunye ne-COX-2 inhibitors zibhekwa njengeendlela ezibalulekileyo zokonyango kwizigulane ze-arthritis , inzuzo kunye nobungozi kufuneka ziqwalaselwe ngamnye kwisigulane ngasinye. Umngcipheko we-cardiac kunye neyona ndlela ifanelekileyo ye-NSAID ukuyisebenzisa kufuneka ihlolwe.
> Imithombo
> IArthritis Foundation. NSAID.
> Bathon, uJoan M. Ingxoxo yee-COX-2 Inhibitors. Johns Hopkins Isikhungo seArthritis.
> Kirkby N, Lundberg M, Wright W, Warner T, uPaul-Clark M, Mitchell, J. COX-2 Ukhusela i-Atherosclerosis Ngokuzimeleyo kwi-Local Vascular Prostacyclin: Ukuchongwa kwe-COX-2 Associated Pathways Implicate Rgl1 kunye ne-Lymphocyte Networks. PLOS One. Juni 2, 2014.